CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NCT06881784 · Phase 3 · Recruiting

PHASEPhase 3

STATUSRecruiting

ENROLLMENT590

EST. COMPLETION2027-12-01

Conditions

NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLCNSCLC (Non-small Cell Lung Carcinoma)NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

daraxonrasibdocetaxel

Study details

SPONSORRevolution Medicines, Inc.

START DATE2025-05-06

Related company profiles

Revolution Medicines Inc

RVMD

Primary source

ClinicalTrials.gov record NCT06881784 ↗

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier: NCT06881784
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record